Investment Analysts’ Recent Ratings Updates for Chimerix (CMRX)

A number of firms have modified their ratings and price targets on shares of Chimerix (NASDAQ: CMRX) recently:

• 3/15/2025 – Chimerix is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/5/2025 – Chimerix had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $8.55 price target on the stock, up previously from $7.00.
• 3/5/2025 – Chimerix had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $8.55 price target on the stock, down previously from $11.00.
• 3/5/2025 – Chimerix had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $8.50 price target on the stock, down previously from $10.00.
• 2/18/2025 – Chimerix had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, up previously from $6.00.
• 2/18/2025 – Chimerix had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.

Chimerix Stock Performance

Shares of NASDAQ:CMRX opened at $8.48 on Thursday. The stock has a market capitalization of $762.66 million, a PE ratio of -9.02 and a beta of 0.32. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $8.49. The firm has a fifty day moving average price of $5.14 and a 200 day moving average price of $2.73.

Insider Buying and Selling

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders sold 20,760 shares of company stock worth $91,175. Corporate insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Chimerix

A number of hedge funds have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C bought a new stake in Chimerix during the fourth quarter valued at about $13,124,000. Rosalind Advisors Inc. bought a new stake in Chimerix during the fourth quarter valued at about $10,614,000. Millennium Management LLC lifted its stake in shares of Chimerix by 6.8% in the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after buying an additional 161,795 shares during the period. Marshall Wace LLP lifted its stake in shares of Chimerix by 1,318.5% in the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock valued at $7,705,000 after buying an additional 2,057,864 shares during the period. Finally, Boxer Capital Management LLC bought a new stake in shares of Chimerix in the fourth quarter valued at about $7,169,000. 45.42% of the stock is currently owned by institutional investors.

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.